Liu S, et al. IMPOWER 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. IASLC 2018, abstract PL02.07.
Mini-tumoren voorspellen ex-vivorespons op PD-1-blokkers
okt 2021 | Immuuntherapie, Longoncologie